
Breast International Group/X
Dec 13, 2024, 15:19
Neoadjuvant treatment with an anthracycline-free regimen in Breast Cancer – Breast International Group
Breast International Group shared a post on X:
“SABCS24.
P3-11-03 poster on results of phase 2 DECRESCENDO study:
Neoadjuvant treatment with an anthracycline-free regimen in patients with HER2-positive, HR-negative, node-negative early breast cancer resulted in a high rate of pCR.”
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 22, 2025, 04:19
Feb 22, 2025, 03:56
Feb 22, 2025, 03:52
Feb 22, 2025, 03:21
Feb 22, 2025, 03:18